2024 ESVS临床实践指南:腹主动脉-髂动脉动脉瘤的管理

2024-02-06 欧洲血管外科学会 Eur J Vasc Endovasc Surg 发表于陕西省

本文主要提供了腹主动脉和髂动脉动脉瘤患者管理的临床实践指南,共提出了160条指导建议,目的是为腹主动脉-髂动脉动脉瘤治疗的最全面、最新和公正的建议。

中文标题:

2024 ESVS临床实践指南:腹主动脉-髂动脉动脉瘤的管理

英文标题:

European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms

发布机构:

欧洲血管外科学会

发布日期:

2024-02-06

简要介绍:

本文主要提供了腹主动脉和髂动脉动脉瘤患者管理的临床实践指南,共提出了160条指导建议,目的是为腹主动脉-髂动脉动脉瘤治疗的最全面、最新和公正的建议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2024+ESVS临床实践指南:腹主动脉-髂动脉动脉瘤的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=973521c0035e6811, title=2024 ESVS临床实践指南:腹主动脉-髂动脉动脉瘤的管理, enTitle=European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms, guiderFrom=Eur J Vasc Endovasc Surg, authorId=0, author=, summary=本文主要提供了腹主动脉和髂动脉动脉瘤患者管理的临床实践指南,共提出了160条指导建议,目的是为腹主动脉-髂动脉动脉瘤治疗的最全面、最新和公正的建议。, cover=https://img.medsci.cn/Random/conference-with-doctors-in-medical-aprons-PT29AAG.jpg, journalId=0, articlesId=null, associationId=638, associationName=欧洲血管外科学会, associationIntro=欧洲血管外科学会开展欧洲血管外科医生的培训(EVST),每年举行一次年会,旨在收集欧洲血管外科医生的培训和教育的信息,并将有关的血管外科研究付诸实践。, copyright=0, guiderPublishedTime=Tue Feb 06 00:00:00 CST 2024, originalUrl=, linkOutUrl=, content=<p>本文主要提供了腹主动脉和髂动脉动脉瘤患者管理的临床实践指南,共提出了160条指导建议,目的是为腹主动脉-髂动脉动脉瘤治疗的最全面、最新和公正的建议。</p>, tagList=[TagDto(tagId=2903, tagName=腹主动脉瘤), TagDto(tagId=486745, tagName=髂动脉动脉瘤)], categoryList=[CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=92, categoryName=血管外科, tenant=100)], articleKeywordId=2903, articleKeyword=腹主动脉瘤, articleKeywordNum=6, guiderKeywordId=2903, guiderKeyword=腹主动脉瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5711, appHits=59, showAppHits=0, pcHits=749, showPcHits=5652, likes=0, shares=8, comments=10, approvalStatus=1, publishedTime=Wed Feb 07 18:02:00 CST 2024, publishedTimeString=2024-02-06, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=FUNNYMAN, createdTime=Wed Feb 07 14:23:05 CST 2024, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Wed Feb 07 16:43:39 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=陕西省, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2024+ESVS临床实践指南:腹主动脉-髂动脉动脉瘤的管理.pdf)])
2024+ESVS临床实践指南:腹主动脉-髂动脉动脉瘤的管理.pdf
下载请点击:
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2224014, encodeId=e21722240141f, content=如何才能下载?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:29:44 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2224015, encodeId=ccd622240153a, content=这个是中文版还是英文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:30:37 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2224035, encodeId=e0592224035a4, content=感觉感谢提供, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:42:37 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2224018, encodeId=115e22240188c, content=太需要这个东西了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:31:28 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2224038, encodeId=d80b222403861, content=腹主动脉-髂动脉动脉瘤的管理, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:43:33 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省)]
    2024-09-04 ms1000001961724935 来自四川省

    如何才能下载?

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2224014, encodeId=e21722240141f, content=如何才能下载?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:29:44 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2224015, encodeId=ccd622240153a, content=这个是中文版还是英文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:30:37 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2224035, encodeId=e0592224035a4, content=感觉感谢提供, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:42:37 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2224018, encodeId=115e22240188c, content=太需要这个东西了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:31:28 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2224038, encodeId=d80b222403861, content=腹主动脉-髂动脉动脉瘤的管理, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:43:33 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省)]
    2024-09-04 ms1000001961724935 来自四川省

    这个是中文版还是英文版

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2224014, encodeId=e21722240141f, content=如何才能下载?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:29:44 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2224015, encodeId=ccd622240153a, content=这个是中文版还是英文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:30:37 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2224035, encodeId=e0592224035a4, content=感觉感谢提供, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:42:37 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2224018, encodeId=115e22240188c, content=太需要这个东西了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:31:28 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2224038, encodeId=d80b222403861, content=腹主动脉-髂动脉动脉瘤的管理, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:43:33 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省)]
    2024-09-04 ms1000001961724935 来自四川省

    感觉感谢提供

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2224014, encodeId=e21722240141f, content=如何才能下载?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:29:44 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2224015, encodeId=ccd622240153a, content=这个是中文版还是英文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:30:37 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2224035, encodeId=e0592224035a4, content=感觉感谢提供, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:42:37 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2224018, encodeId=115e22240188c, content=太需要这个东西了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:31:28 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2224038, encodeId=d80b222403861, content=腹主动脉-髂动脉动脉瘤的管理, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:43:33 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省)]
    2024-09-04 ms1000001961724935 来自四川省

    太需要这个东西了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2224014, encodeId=e21722240141f, content=如何才能下载?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:29:44 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2224015, encodeId=ccd622240153a, content=这个是中文版还是英文版, beContent=null, objectType=guider, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:30:37 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2224035, encodeId=e0592224035a4, content=感觉感谢提供, beContent=null, objectType=guider, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:42:37 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2224018, encodeId=115e22240188c, content=太需要这个东西了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:31:28 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2224038, encodeId=d80b222403861, content=腹主动脉-髂动脉动脉瘤的管理, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3afd9450497, createdName=ms1000001961724935, createdTime=Wed Sep 04 15:43:33 CST 2024, time=2024-09-04, status=1, ipAttribution=四川省)]
    2024-09-04 ms1000001961724935 来自四川省

    腹主动脉-髂动脉动脉瘤的管理

    0

拓展阅读

Nat Immunol:内皮功能障碍与动脉粥样硬化斑块巨噬细胞共同驱动腹主动脉瘤形成

本研究通过整合多种实验方法和模型,系统地分析了内皮功能障碍和巨噬细胞在AAA形成中的作用。研究结果不仅揭示了AAA的发病机制,还为开发新的治疗策略提供了潜在的靶点。

Adv Sci 浙江大学医学院蔡哲钧、刘震杰教授联合武汉协和医院李飞教授揭示IRF8在腹主动脉瘤发生发展中的作用及机制

该研究发现在人类和小鼠模型AAA组织样本中存在大量DC细胞浸润,并且DC特异性过表达Irf8或敲除能够显著改变弹性蛋白酶诱导的动脉瘤扩张。

Nat Cardiovasc Res 中南大学湘雅药学院张政团队揭示TRPM7通道激酶驱动腹主动脉瘤发生的分子机制

临床药物FTY720可通过抑制TRPM7通道活性改善AAA。这一发现不仅阐明了TRPM7在AAA中的分子调控机制,更为AAA的防治提供了新的治疗策略,具有潜在的临床转化潜能。

降脂药PCSK9抑制剂,还有望防治腹主动脉瘤!阜外医院王淼等研究

该前蛋白转化酶枯草溶菌素9(PCSK9)在巨噬细胞炎症和弹性蛋白降解过程中起关键介导作用,从而促进腹主动脉瘤形成和进展。

ATVB 中国医学科学院王淼/陈厚早教授团队合作揭示降脂明星靶点PCSK9的炎症调控关键作用及其防治腹主动脉瘤中的应用

该研究揭示了PCSK9(前蛋白转化酶枯草溶菌素/胰蛋白酶9)在AAA形成中的重要作用,为防治AAA提供了新的药物靶点和干预手段。

Cardiovasc Res:高平进/林静蓉团队发现激活β3-AR促进血管外周淋巴管新生抑制主动脉夹层/主动脉瘤发生

激活β3-AR通过调控脂肪VEGF-C介导管周淋巴管新生从而抑制AD/AA的发生,阐明了淋巴管新生在血管损伤中的保护机制,并提出脂肪-淋巴管相互作用的概念。

2014 USPSTF 腹主动脉瘤筛查推荐声明

美国预防医学工作组(USPSTF,U.S. Preventive Services Task Force) · 2014-06-24

2017 WVS指南:腹主动脉瘤破裂患者的转诊

西方血管学会(WVS,Western Vascular Society) · 2017-02-20

2017 CTFPHC建议:基层医疗中腹主动脉瘤的筛查

加拿大预防保健工作组(CTFPHC,Canadian Task Force on Preventive Health Care) · 2017-09-11

2017 SVS实践指南:腹主动脉瘤患者的护理

血管外科学会(SVS,Society for Vascular Surgery) · 2017-12-20

2019 ESVS临床实践指南:腹主动脉-髂动脉瘤的管理

欧洲血管外科学会(ESVS,The European Society for Vascular Surgery) · 2018-12-05